Biomarin Pharmaceutical Inc (BMRN.OQ)
BMRN.OQ on NASDAQ Stock Exchange Global Select Market
74.43USD
30 Oct 2020
74.43USD
30 Oct 2020
Change (% chg)
$0.01 (+0.01%)
$0.01 (+0.01%)
Prev Close
$74.42
$74.42
Open
$73.74
$73.74
Day's High
$74.54
$74.54
Day's Low
$72.45
$72.45
Volume
649,796
649,796
Avg. Vol
692,621
692,621
52-wk High
$131.86
$131.86
52-wk Low
$68.25
$68.25
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2020 | Jun '20 | 429.48 | -0.161 |
| Mar '20 | 502.07 | 0.435 | |
| FY 2019 | Dec '19 | 454.44 | 0.084 |
| Sep '19 | 461.10 | 0.296 | |
| Jun '19 | 387.76 | -0.209 | |
| Mar '19 | 400.74 | -0.317 | |
| FY 2018 | Dec '18 | 353.21 | 0.005 |
| Sep '18 | 391.71 | -0.071 | |
| Jun '18 | 372.85 | -0.095 | |
| Mar '18 | 373.45 | -0.277 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-20 | 18 | 474.99 | 522.00 | 420.33 | 494.44 |
| Quarter Ending Mar-21 | 7 | 482.21 | 514.00 | 466.78 | 539.79 |
| Year Ending Dec-20 | 22 | 1,859.54 | 1,917.00 | 1,800.64 | 1,946.00 |
| Year Ending Dec-21 | 22 | 2,035.42 | 2,324.00 | 1,867.60 | 2,204.40 |
| Earnings (per share) | |||||
| Quarter Ending Dec-20 | 17 | 2.75 | 4.18 | -0.33 | -0.05 |
| Quarter Ending Mar-21 | 6 | 0.02 | 0.19 | -0.03 | 0.36 |
| Year Ending Dec-20 | 20 | 4.18 | 4.93 | 3.62 | 0.21 |
| Year Ending Dec-21 | 20 | 0.51 | 2.50 | -0.54 | 1.06 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 113.98 | 33.33 | 42.75 | |
| P/E High - Last 5 Yrs. | -- | 43.30 | 46.69 | |
| P/E Low - Last 5 Yrs. | -- | 25.39 | 25.34 | |
| Beta | 0.69 | 0.86 | 0.85 | |
| Price to Sales (TTM) | 7.31 | 4.03 | 11.39 | |
| Price to Book (MRQ) | 4.17 | 3.78 | 4.25 | |
| Price to Tangible Book (MRQ) | 5.18 | 4.37 | 5.74 | |
| Price to Cash Flow (TTM) | 58.22 | 20.20 | 33.67 | |
| % Owned Institutions | -- | 0.00 | 0.00 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.66 | 1.53 | |
| Dividend Yield - 5 Year Avg | -- | 1.61 | 1.50 | |
| Dividend 5 Year Growth Rate | -- | 4.25 | 5.03 | |
| Payout Ratio(TTM) | 0.00 | 46.98 | 44.04 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 10.76 | 0.78 | -0.33 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 20.46 | 5.02 | 4.99 | |
| Sales - 5 Yr. Growth Rate | 17.86 | 5.90 | 6.19 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 22.77 | 2.52 | 1.26 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 210.38 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 8.29 | 8.51 | |
| Capital Spending - 5 Yr. Growth Rate | 6.90 | 13.24 | 13.08 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 2.34 | 2.49 | 2.53 |
| Current Ratio (MRQ) | 3.26 | 3.40 | 3.42 |
| LT Debt to Equity (MRQ) | 33.31 | 12.56 | 14.38 |
| Total Debt to Equity (MRQ) | 44.85 | 16.69 | 18.86 |
| Interest Coverage (TTM) | -4.54 | 11.28 | 14.74 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 78.23 | 54.49 | 54.40 | |
| Gross Margin - 5 Yr. Avg. | 80.38 | 54.28 | 53.91 | |
| EBITD Margin (TTM) | 5.18 | -- | -- | |
| EBITD - 5 Yr. Avg | -8.29 | 18.91 | 11.68 | |
| Operating Margin (TTM) | 3.19 | 15.37 | -11.17 | |
| Operating Margin - 5 Yr. Avg. | -17.70 | 14.62 | 5.37 | |
| Pre-Tax Margin (TTM) | 3.20 | 15.82 | -13.18 | |
| Pre-Tax Margin - 5 Yr. Avg. | -19.33 | 14.91 | 5.14 | |
| Net Profit Margin (TTM) | 6.62 | 12.03 | -16.90 | |
| Net Profit Margin - 5 Yr. Avg. | -15.01 | 11.24 | 1.74 | |
| Effective Tax Rate (TTM) | -106.80 | 19.27 | 19.94 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 22.32 | 22.40 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 615,493 | 1,003,736,451 | 858,318,634 | |
| Net Income/Employee (TTM) | 40,739 | 115,590,039 | 98,723,331 | |
| Receivable Turnover (TTM) | 4.87 | 5.51 | 5.45 | |
| Inventory Turnover (TTM) | 0.61 | 2.52 | 3.45 | |
| Asset Turnover (TTM) | 0.38 | 0.80 | 0.78 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 2.52 | 10.19 | 9.45 | |
| Return on Assets - 5 Yr. Avg. | -4.79 | 11.25 | 10.75 | |
| Return on Investment (TTM) | 2.90 | 12.64 | 12.00 | |
| Return on Investment - 5 Yr. Avg. | -5.56 | 14.08 | 13.46 | |
| Return on Equity (TTM) | 3.95 | 14.16 | 13.74 | |
| Return on Equity - 5 Yr. Avg. | -7.37 | 16.82 | 16.12 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 14.27 | 15.12 | 17.86 |
| EPS (TTM) % | 69.45 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Biomarin Pharmaceutical Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -0.73 | 1.65 | 99 | 32 |
| 13 Week | -37.88 | -37.85 | 27 | 20 |
| 26 Week | -15.54 | -26.88 | 76 | 23 |
| 52 Week | 1.67 | -5.56 | 99 | 56 |
| YTD | -11.97 | -13.02 | 99 | 55 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive
- UPDATE 3-U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive
- U.S. FDA declines to approve Biomarin's gene therapy for bleeding disorder
- BRIEF-BioMarin Promotes Company Veteran Brian Mueller To Executive Vice President, CFO
- BRIEF-BioMarin Provides New Data from Study Of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 781 |
| Total Shares Held: | 184,261,092 |
| 3 Mo. Net Change: | 971,721 |
| # New Positions: | 21 |
| # Closed Positions: | 23 |
| # Increased Positions: | 93 |
| # Reduced Positions: | 79 |
| # Net Buyers: | 14 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.